Impact of Ivabradine on renal function in septic patient with early renal impairment
SOBHY, AMR;
Abstract
Background: Acute kidney injury (AKI) with sepsis increases mortality significantly. The pathophysiology of AKI
during sepsis is complex and multifactorial. Lower heart rate is associated with better survival in patients with
multiple organ dysfunction syndrome (MODS), a disease mostly caused by sepsis. In our study, we hypnotized that
use of ivardrabine as heart rate reducing agent in septic patient with renal impairment may improve renal function.
Results: Fifty patients with sepsis with early renal impairment were divided in 1: 1 ratio to receive Ivabradine
(group I) or not (group C). The average age of the included patients was almost 45 years, chest disorders were the
main cause of sepsis in both groups. There were statistically significant differences between both groups in terms
of reduction of heart rate group (I) (68.13 ± 3.34) versus (group C) (87.04 ± 3.23) and (P < 0.001) also, improvement
in eGFR by Cystatin c in group (I) (103.32 ± 6.96) versus (group C) (96.25 ± 6.36) and (P < 0.001) also vasopressor
dosage consumption (P < 0.001). As regards secondary outcomes, there were no statistically significant differences
between study’s groups in terms of length of hospital stay (P = 0.390), need for hemodialysis (P = 0.384), and
mortality (P = 1.000).
Conclusions: We concluded that Ivabradine as an adjuvant therapy in septic patients with renal impairment is
promising agent to reduce such impairment.
during sepsis is complex and multifactorial. Lower heart rate is associated with better survival in patients with
multiple organ dysfunction syndrome (MODS), a disease mostly caused by sepsis. In our study, we hypnotized that
use of ivardrabine as heart rate reducing agent in septic patient with renal impairment may improve renal function.
Results: Fifty patients with sepsis with early renal impairment were divided in 1: 1 ratio to receive Ivabradine
(group I) or not (group C). The average age of the included patients was almost 45 years, chest disorders were the
main cause of sepsis in both groups. There were statistically significant differences between both groups in terms
of reduction of heart rate group (I) (68.13 ± 3.34) versus (group C) (87.04 ± 3.23) and (P < 0.001) also, improvement
in eGFR by Cystatin c in group (I) (103.32 ± 6.96) versus (group C) (96.25 ± 6.36) and (P < 0.001) also vasopressor
dosage consumption (P < 0.001). As regards secondary outcomes, there were no statistically significant differences
between study’s groups in terms of length of hospital stay (P = 0.390), need for hemodialysis (P = 0.384), and
mortality (P = 1.000).
Conclusions: We concluded that Ivabradine as an adjuvant therapy in septic patients with renal impairment is
promising agent to reduce such impairment.
Other data
Title | Impact of Ivabradine on renal function in septic patient with early renal impairment | Authors | SOBHY, AMR | Keywords | Mortality;Renal impairment;Sepsis;Cystatin c;Ivabradine | Issue Date | 13-Jul-2021 | Publisher | SPIRNGER OPEN | Journal | Ain Shams Journal of Anesthesiology | Volume | 13 | Issue | 1 | Start page | 45 | End page | 52 | DOI | 10.1186/s42077-021-00162-6 |
Attached Files
File | Description | Size | Format | Existing users please Login |
---|---|---|---|---|
Sobhy2021_Article_ImpactOfIvabradineOnRenalFunct.pdf | 670.36 kB | Adobe PDF | Request a copy |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.